Richard Saynor, Sandoz CEO
Novartis' Sandoz founds new initiative to expand biosimilar use more globally
Novartis’ generics giant Sandoz has been in the biosimilars space since the very beginning, and as uptake has stalled even in more developed markets like the US, countries with smaller economies have also struggled to gain access to new biosimilars.
Sandoz on Tuesday launched a new initiative called “Act4Biosimilars,” led by a steering committee that includes Sandoz exec Michael Wiechmann, the company’s global head of medical affairs.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
